O18971
PR
Gene name |
PPARG (NR1C3) |
Protein name |
Peroxisome proliferator-activated receptor gamma |
Names |
PPAR-gamma, Nuclear receptor subfamily 1 group C member 3 |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:281993 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for O18971
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-O18971-F1 | Predicted | AlphaFoldDB |
31 variants for O18971
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs720514826 | 18 | A>V | No | EVA | |
| rs476310876 | 20 | T>P | No | EVA | |
| rs525744416 | 45 | I>M | No | EVA | |
| rs452359259 | 61 | D>G | No | EVA | |
| rs432327030 | 62 | I>F | No | EVA | |
| rs209092270 | 65 | F>L | No | EVA | |
| rs466778291 | 104 | S>R | No | EVA | |
| rs445119945 | 105 | A>G | No | EVA | |
| rs478173188 | 106 | I>T | No | EVA | |
| rs450907359 | 108 | V>G | No | EVA | |
| rs480767295 | 111 | V>L | No | EVA | |
| rs440471305 | 124 | S>R | No | EVA | |
| rs479780463 | 126 | P>A | No | EVA | |
| rs458197603 | 150 | H>P | No | EVA | |
| rs439870592 | 154 | H>Q | No | EVA | |
| rs476183196 | 155 | A>S | No | EVA | |
| rs476183196 | 155 | A>T | No | EVA | |
| rs456056791 | 155 | A>V | No | EVA | |
| rs444063002 | 156 | C>F | No | EVA | |
| rs473796224 | 158 | G>R | No | EVA | |
| rs474657037 | 178 | L>R | No | EVA | |
| rs132979274 | 196 | Q>* | No | EVA | |
| rs441851156 | 275 | F>C | No | EVA | |
| rs474750486 | 281 | N>S | No | EVA | |
| rs453277419 | 319 | E>D | No | EVA | |
| rs435684809 | 323 | E>Q | No | EVA | |
| rs441144143 | 328 | A>D | No | EVA | |
| rs452486012 | 415 | F>L | No | EVA | |
| rs471018615 | 415 | F>V | No | EVA | |
| rs437316777 | 423 | G>V | No | EVA | |
| rs109613657 | 448 | Q>H | No | EVA |
No associated diseases with O18971
10 regional properties for O18971
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| repeat | Armadillo | 116 - 157 | IPR000225-1 |
| repeat | Armadillo | 159 - 203 | IPR000225-2 |
| repeat | Armadillo | 201 - 242 | IPR000225-3 |
| repeat | Armadillo | 245 - 284 | IPR000225-4 |
| repeat | Armadillo | 286 - 326 | IPR000225-5 |
| repeat | Armadillo | 328 - 368 | IPR000225-6 |
| repeat | Armadillo | 370 - 410 | IPR000225-7 |
| repeat | Armadillo | 413 - 453 | IPR000225-8 |
| domain | Importin-alpha, importin-beta-binding domain | 1 - 105 | IPR002652 |
| repeat | Atypical Arm repeat | 467 - 516 | IPR032413 |
Functions
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
9 GO annotations of molecular function
| Name | Definition |
|---|---|
| chromatin binding | Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. |
| DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| DNA-binding transcription factor activity | A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons. |
| DNA-binding transcription repressor activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that represses or decreases the transcription of specific gene sets transcribed by RNA polymerase II. |
| E-box binding | Binding to an E-box, a DNA motif with the consensus sequence CANNTG that is found in the promoters of a wide array of genes expressed in neurons, muscle and other tissues. |
| nuclear receptor activity | A DNA-binding transcription factor activity regulated by binding to a ligand that modulates the transcription of specific gene sets transcribed by RNA polymerase II. Nuclear receptor ligands are usually lipid-based (such as a steroid hormone) and the binding of the ligand to its receptor often occurs in the cytoplasm, which leads to its tranlocation to the nucleus. |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. |
| transcription cis-regulatory region binding | Binding to a specific sequence of DNA that is part of a regulatory region that controls transcription of that section of the DNA. The transcribed region might be described as a gene, cistron, or operon. |
| zinc ion binding | Binding to a zinc ion (Zn). |
24 GO annotations of biological process
| Name | Definition |
|---|---|
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| cell fate commitment | The commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field. |
| cellular response to insulin stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms. |
| epithelial cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium. |
| fatty acid metabolic process | The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis. |
| hormone-mediated signaling pathway | The series of molecular signals mediated by the detection of a hormone. |
| macrophage derived foam cell differentiation | The process in which a monocyte acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. |
| negative regulation of cholesterol storage | Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. |
| negative regulation of DNA-templated transcription | Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. |
| negative regulation of inflammatory response | Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response. |
| negative regulation of transcription by RNA polymerase II | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of fat cell differentiation | Any process that activates or increases the frequency, rate or extent of adipocyte differentiation. |
| positive regulation of fatty acid metabolic process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving fatty acids. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| regulation of circadian rhythm | Any process that modulates the frequency, rate or extent of a circadian rhythm. A circadian rhythm is a biological process in an organism that recurs with a regularity of approximately 24 hours. |
| regulation of DNA-templated transcription | Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. |
| regulation of fat cell differentiation | Any process that modulates the frequency, rate or extent of adipocyte differentiation. |
| regulation of lipid metabolic process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| response to lipid | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid stimulus. |
| retinoic acid receptor signaling pathway | The series of molecular signals generated as a consequence of a retinoic acid receptor binding to one of its physiological ligands. |
| rhythmic process | Any process pertinent to the generation and maintenance of rhythms in the physiology of an organism. |
| white fat cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole. |
28 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9TTR7 | NR2F2 | COUP transcription factor 2 | Bos taurus (Bovine) | PR |
| Q90733 | NR2F2 | COUP transcription factor 2 | Gallus gallus (Chicken) | PR |
| P68306 | THRB | Thyroid hormone receptor beta | Gallus gallus (Chicken) | PR |
| A7X8B3 | PGR | Progesterone receptor | Pan troglodytes (Chimpanzee) | SS |
| P10588 | NR2F6 | Nuclear receptor subfamily 2 group F member 6 | Homo sapiens (Human) | PR |
| P06401 | PGR | Progesterone receptor | Homo sapiens (Human) | EV |
| P10589 | NR2F1 | COUP transcription factor 1 | Homo sapiens (Human) | PR |
| O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (Human) | PR |
| P24468 | NR2F2 | COUP transcription factor 2 | Homo sapiens (Human) | PR |
| P49116 | NR2C2 | Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (Human) | PR |
| P37231 | PPARG | Peroxisome proliferator-activated receptor gamma | Homo sapiens (Human) | PR |
| P35396 | Ppard | Peroxisome proliferator-activated receptor delta | Mus musculus (Mouse) | PR |
| P43136 | Nr2f6 | Nuclear receptor subfamily 2 group F member 6 | Mus musculus (Mouse) | PR |
| P43135 | Nr2f2 | COUP transcription factor 2 | Mus musculus (Mouse) | PR |
| Q00175 | Pgr | Progesterone receptor | Mus musculus (Mouse) | SS |
| Q9Z0Y9 | Nr1h3 | Oxysterols receptor LXR-alpha | Mus musculus (Mouse) | PR |
| O62807 | PPARG | Peroxisome proliferator-activated receptor gamma | Sus scrofa (Pig) | PR |
| O09018 | Nr2f2 | COUP transcription factor 2 | Rattus norvegicus (Rat) | PR |
| Q63449 | Pgr | Progesterone receptor | Rattus norvegicus (Rat) | SS |
| Q8SQ01 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Macaca mulatta (Rhesus macaque) | PR |
| G5EFF5 | daf-12 | Nuclear hormone receptor family member daf-12 | Caenorhabditis elegans | PR |
| O45460 | nhr-54 | Nuclear hormone receptor family member nhr-54 | Caenorhabditis elegans | PR |
| Q21006 | nhr-34 | Nuclear hormone receptor family member nhr-34 | Caenorhabditis elegans | PR |
| O17928 | nhr-52 | Nuclear hormone receptor family member nhr-52 | Caenorhabditis elegans | PR |
| Q21878 | nhr-1 | Nuclear hormone receptor family member nhr-1 | Caenorhabditis elegans | PR |
| O18141 | nhr-79 | Nuclear hormone receptor family member nhr-79 | Caenorhabditis elegans | PR |
| Q20765 | nhr-7 | Nuclear hormone receptor family member nhr-7 | Caenorhabditis elegans | PR |
| Q6PH18 | nr2f1b | Nuclear receptor subfamily 2 group F member 1-B | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MGETLGDALI | DPESEPFAVT | VSARTSQEIT | MVDTEMPFWP | TNFGISSVDL | SMMDDHSHAF |
| 70 | 80 | 90 | 100 | 110 | 120 |
| DIKPFTTVDF | SSISTPHYED | IPFPRADPMV | ADYKYDLKLQ | EYQSAIKVEP | VSPPYYSEKT |
| 130 | 140 | 150 | 160 | 170 | 180 |
| QLYSKPHEEP | SNSLMAIECR | VCGDKASGFH | YGVHACEGCK | GFFRRTIRLK | LIYDRCDLNC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| RIHKKSRNKC | QYCRFQKCLA | VGMSHNAIRF | GRMPQAEKEK | LLAEISSDID | QLNPESADLR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| ALAKHLYDSY | IKSFPLTKAK | ARAILTGKTT | DKSPFVIYDM | NSLMMGEDKI | KFKHISPLQE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| PSKEVAIRIF | QGCQFRSVEA | VQEITEYAKN | IPGFVNLDLN | DQVTLLKYGV | HEIIYTMLAS |
| 370 | 380 | 390 | 400 | 410 | 420 |
| LMNKDGVLIS | EGQGFMTREF | LKSLRKPFGD | FMEPKFEFAV | KFNALELDDS | DLAIFIAVII |
| 430 | 440 | 450 | 460 | 470 | 480 |
| LSGDRPGLLN | VKPIEDIQDN | LLQALELQLK | LNHPESSQLF | AKLLQKMTDL | RQIVTEHVQL |
| 490 | 500 | ||||
| LQVIKKTETD | MSLHPLLQEI | YKDLY |